Please sign in to follow a disease.
Massive european TB registry aims to map the disease and sharpen treatment
NCT ID NCT07677904
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study collects long-term data from tuberculosis patients across Europe to better understand the disease and its treatment. Researchers track risk factors, diagnostic details, side effects, and outcomes for both drug-sensitive and drug-resistant TB. The goal is to identify what leads to successful treatment and to develop a risk score for mortality. The registry does not test a new drug or intervention but gathers real-world evidence to guide future care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could identify factors that improve TB treatment outcomes and help develop a mortality risk score, guiding better care across Europe.
- What could go wrong
- As an observational registry, it does not test a new treatment, so direct patient benefits are not guaranteed. Data quality depends on consistent reporting from many sites.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2040
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Inpatients in tuberculosis care
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of Tuberculosis * Age ≥ 18 years * Capacity to provide informed consent * Written informed consent to participate in the study Exclusion Criteria: * Lack of capacity to provide informed consent * Age \< 18 years
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tuberculosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IRCCS Ospedale Sacro Cuore Don Calabria
Negrar, Verona, 37024, Italy
-
Research Center Borstel, Leibniz Lung Center
Borstel, Schleswig-Holstein, 23845, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Can simple sputum and urine tests catch tuberculosis earlier?
- Can a common virus be turned into a TB vaccine? scientists test VIR-1778
- Fish oil meets TB drugs: can Omega-3 help clear infection faster?
- Can starting TB treatment immediately save lives in HIV sepsis?
- Can a 4-Drug combo cut TB treatment time in half?